NEW YORK, Jan. 17, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, chairman and CEO will be presenting at the 9th Annual BIO Asia International Conference. The meeting will take place January 31 –February 1 at the Ritz Carlton Osaka in Osaka, Japan. Dr. Chain will be presenting on Tuesday, January 31st at 4:00 p.m. in the Georgian Room.
"Intellect Neurosciences is at the forefront of Alzheimer's research, with a rich pipeline and intellectual property portfolio and licensed products in late-stage clinical development," said Dr. Chain. "Since part of our patent portfolio is in China, India and Japan we look forward to interacting with the Asian biotechnology and investor community to discuss potential partnerships and other opportunities for building our IP and technology portfolio of ground-breaking treatments for Alzheimer's and other devastating neurodegenerative diseases."
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.
The company is currently developing products based on three platform technologies: ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology which underlies a product in Phase 3 clinical trials licensed to major pharmaceutical companies. ANTISENILIN also underlies IN-N01, a humanized monoclonal antibody being developed by the company. RECALL-VAX is a therapeutic vaccine technology that underlies three preclinical drug candidates, RV01, RVO2 which target beta amyloid and delta tau protein, respectively and RVO3 which is a combination of the two. IN-N01-OX2 is the first candidate to emerge from the company's CONJUMAB-A platform technology, based on a completely novel application of antibody drug conjugates (ADCs) in which the antibody is chemically conjugated to a small molecule (OX2) that has potent neuroprotective properties both as an antioxidant and inhibitor of protein aggregation.
Intellect is seeking to partner/license its platform technologies on a product- by-product basis to develop antibody-drug conjugates and therapeutic vaccines. RECALL-VAX and CONJUMAB-A have potential applications for treatment of several serious diseases such as Alzheimer's, Parkinson's, Huntington's, Cerebral Amyloid Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease, Cortical Basal Degeneration, Age-Related Macular Degeneration, Glaucoma, and Peripheral Amyloidosis.
The company recently licensed OX1 a small molecule multimodal antioxidant to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit www.intellectns.com.
About the BIO Asia International Conference
The 2012 BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian pharmaceutical and biotech companies interested in research collaborations and license agreements. BIO brings more than ten years of experience and expertise in biotech and pharmaceutical partnering to the Asia-Pacific region, after successfully establishing the largest partnering-focused events in the U.S. and Europe.
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2011, and in our Quarterly Report on Form 10-Q/A for the quarterly period ended September 30, 2011, filed on November 10, 2011.
JQA Partners, LLC
SOURCE Intellect Neurosciences, Inc.